Mirk/Dyrk1B mediates G0/G1 to S of cell cycle and cell survival in both ovarian cancer and NSCLC cells may be associated with MAPK/ERK signaling. Therefore, simultaneous inhibition of Mirk/ Dyrk1B and MAPK/ERK may be a novel target for treat ment of human cancer. Introduction Two common epigenetic regulations are DNA methyla selleckbio tion and histone acetylation, which modify DNA and histone interactions within chromatins and account for the increase or decrease in gene expression. DNA hypermethylation has been shown to inhibit gene transcription, thus reducing gene expression. Methylation and deacetylation have been found to play a key role in malignant disorders. Inhibitors of these processes, such as methyltransferase inhibitors and histone deacetylase inhibitors, are novel anti cancer agents.

Two DNA methyltransferase inhibitors, azacitidine and decitabine, and a histone deacetylase inhibitor, vorinostat, have been licensed for clinical use. Phenethyl isothiocyanate belongs to the family of natural isothiocyanates, which are found in a wide variety of cruciferous vegetables, and are released when the vegetables are cut or masticated. PEITC has been proven to be an effective HDAC inhibitor, and is able to induce growth arrest and apoptosis in cancer cells both in vitro and in vivo. Breast cancer is the most commonly diagnosed cancer among women, accounting for more than 1 in 4 cancers. After lung cancer, breast cancer is the leading cause of cancer death in women. Chemotherapy is a mainstay in breast cancer therapy. New agents are being actively sought.

Paclitaxel is a widely used chemo therapy drug in the treatment of breast cancer, lung cancer, and ovarian cancer. It was first discov ered in 1967, entered clinical trials in 1984, and has been a leading chemotherapeutic agent ever since. The mechanism of action of pacli taxel involves its interference with microtubule assembly. Paclitaxel prevents the disassembly of microtubules during mitosis. When taxol binds to tubulin, the microtubules become locked in polymerized state, and thus the cells are restricted from G2 to M phase transi tion. The end result is that the cells are not able to replicate. Another effect of taxol is that it inhibits the anti apoptosis protein Bcl 2, and induces apoptosis in cancer cells. However, paclitaxel, like most other chemotherapy drugs, has a high level of toxicity as well as a multitude of side effects.

The consequence of the toxicity of taxol at a higher dosage is neuropathy which limits its use in patients. Furthermore, cancer cells develop resistance to taxol after prolonged use. It has AV-951 been shown in this laboratory that PEITC is a HDAC inhibitor and can suppress HDAC enzyme activity and decrease HDAC enzyme expression in prostate cancer, leukemia, and myeloma cells. An interesting is that some isothionates have minimal toxicity to normal cells.